What Convergent Therapeutics does

Convergent Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation targeted radiotherapies for cancer, with a primary focus on metastatic castration-resistant prostate cancer (mCRPC). Founded in 2021 as a spinout of Cornell University and headquartered in Cambridge, Massachusetts, the company operates a proprietary alpha-emitting radioantibody platform — licensed from Weill Cornell Medicine and built on Dr. Neil Bander's pioneering PSMA antibody research — that pairs tumor-targeting monoclonal antibodies (e.g., rosopatamab/J591) with the alpha-emitting radionuclide Actinium-225 (Ac-225) via a tetraxetan chelator, delivering short-range, high-energy radiation that causes irreparable double-strand DNA damage in cancer cells while sparing healthy tissue.

Its lead and most advanced asset, CONV01-α (Ac-225 rosopatamab tetraxetan), is a PSMA-directed radioantibody currently in a Phase 2 trial (CONVERGE-01) that has reported positive interim data at ASCO 2026 in Lu-PSMA-exposed mCRPC, including a median radiographic progression-free survival of 8.4 months and a tolerability profile that the company characterizes as best-in-class, supporting plans for a pivotal Phase 3 study. The same platform underpins a broader discovery-stage pipeline of novel α-radioantibodies against undisclosed validated targets in solid tumors beyond prostate cancer, with combination strategies (PD-1 inhibitors and β-radiopharmaceuticals) under investigation. Ac-225 supply is secured through layered partnerships with NorthStar Medical Radioisotopes (including expanded co-located Wisconsin manufacturing announced in January 2026), IONETIX, and Cardinal Health.

Convergent is privately held and pre-revenue, having raised approximately $130 million across a $90 million Series A led by OrbiMed and RA Capital Management (May 2023) and a $40 million Series A extension led by Novo Holdings (September 2024), with Invus also participating. The company is funded to advance clinical development rather than generate commercial revenue; future revenue is expected to come from the sale or licensing of approved radiopharmaceutical therapies, though no pricing model or commercial product has been disclosed. Leadership includes Dr. Philip Kantoff (CEO, Co-Founder; former Chairman of Medicine at Memorial Sloan Kettering), Alexander Brown (COO), Eric Sullivan (CFO), Dr. Richard Messmann (CMO, formerly the global clinical lead for PLUVICTO/LOCAMETZ at Novartis/AAA), Elizabeth Montgomery (Chief People Officer), and Andrew Davis (Chief Business and Strategy Officer), with Scott Myers serving as Chairman.

Name

Convergent Therapeutics

Legal name

Convergent Therapeutics, Inc.

Website

https://convergentrx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Convergent Therapeutics is a clinical-stage, Cornell-spinout biotechnology company developing alpha-emitting radioantibody therapies — led by CONV01-α for metastatic castration-resistant prostate cancer — and serving oncology patients through targeted radiopharmaceuticals built on a proprietary Ac-225 platform.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

Keywords

• Radiopharmaceutical therapy
• Prostate cancer treatment
• Targeted alpha therapy
• Radioantibody platform
• Oncology drug development

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations

Revenue model

1. Pre-revenue / R&D-stage development: Convergent Therapeutics is a clinical-stage biotechnology company that has not yet generated product revenue. The company is funded by venture capital (OrbiMed, RA Capital, Novo Holdings, Invus) and is developing its lead asset CONV01-α through Phase 2 clinical trials with the intent of pursuing regulatory approval and commercialization. Future revenue would be derived from selling radiopharmaceutical therapies or licensing them; the company has licensed its underlying platform technology from Cornell University.

Go-to-market motion1 record

Core offering

Convergent Therapeutics is developing alpha-emitting radioantibody therapies for cancer, with its lead asset CONV01-α (Ac-225 rosopatamab tetraxetan) targeting prostate-specific membrane antigen (PSMA) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The proprietary Cornell-licensed platform pairs tumor-targeting monoclonal antibodies with the alpha-emitting radionuclide Actinium-225 to deliver short-range, high-energy radiation directly into cancer cells. The company is also advancing a discovery-stage pipeline of novel α-radioantibodies against additional validated solid tumor targets.

Product overview

Convergent Therapeutics is a clinical-stage biotechnology company developing a single integrated radioantibody platform — a Cornell-licensed technology that pairs tumor-targeting monoclonal antibodies with alpha-emitting radionuclides (most prominently Actinium-225). Its lead and most advanced asset, CONV01-α (Ac-225 rosopatamab tetraxetan), is a PSMA-targeted radioantibody currently in Phase 2 (CONVERGE-01) trials for metastatic castration-resistant prostate cancer and serves as the clinical proof-of-concept for the platform. The same platform feeds a broader pipeline of novel α-radioantibodies against undisclosed validated targets in solid tumors, with combinations of CONV01-α with PD-1 inhibitors and β-radiopharmaceuticals also under investigation. Together, the platform, the lead CONV01-α asset, and the discovery-stage novel α-radioantibody programs form a unified targeted-radiotherapy portfolio aimed at precision, potency, and safety in oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• CONV01-α (Ac-225 rosopatamab tetraxetan)
• Novel α-Radioantibodies Pipeline

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Eli Lilly: Lilly acquired POINT Biopharma to access PSMA-targeted radioligand therapy, and is a large-cap incumbent expanding into radiopharmaceuticals. Its scale and oncology commercial reach make it a relevant competitive force even though its core business is far broader.
• AstraZeneca: AstraZeneca acquired Fusion Pharmaceuticals to anchor a radioconjugate platform built around alpha emitters including Ac-225, directly competing with Convergent's platform approach and serving as a potential acquirer or partner.
• Bayer: Bayer commercializes Xofigo (radium-223) for mCRPC and has historically been a leader in radiopharmaceuticals. As a large incumbent with urological oncology commercial infrastructure, Bayer is a relevant competitive and partnership reference point.
• Bristol Myers Squibb (RayzeBio): BMS acquired RayzeBio, a clinical-stage developer of actinium-225-based radiopharmaceuticals for solid tumors, making it a direct platform and modality peer. RayzeBio's pipeline (RYZ101 in GEP-NETs and others) overlaps Convergent's alpha-emitter strategy.

Direct peers

• Lantheus Holdings: Lantheus acquired POINT Biopharma and is advancing PNT2002, a PSMA-targeted radioligand therapy for mCRPC, putting it in direct clinical and commercial competition with CONV01-α in the same patient population.
• Novartis: Novartis commercializes Pluvicto (Lu-PSMA-617) and Locametz — the first approved PSMA-targeted radioligand therapy for mCRPC and the direct standard of care Convergent aims to differentiate against. Convergent's CMO previously led PLUVICTO's development at Novartis/AAA, underscoring direct comparability.
• Fusion Pharmaceuticals: Fusion (acquired by AstraZeneca) is developing FPI-2265, an actinium-225-based PSMA radioligand therapy, the most direct alpha-emitter competitor to CONV01-α in mCRPC. Convergent's CMO previously led FPI-2265 development at Fusion.
• ITM Isotope Technologies Munich: ITM is a specialized radiopharmaceutical company developing targeted radionuclide therapies and diagnostics, including in oncology, with proprietary isotope production capabilities that overlap with Convergent's radioligand/radioantibody development focus.
• Telix Pharmaceuticals: Telix is developing PSMA-targeted radiopharmaceuticals (including TLX591, a 177Lu-labeled anti-PSMA antibody using a similar antibody-based targeting approach), making it a direct platform and indication peer to Convergent.

Emerging players

• Actinium Pharmaceuticals: Actinium Pharmaceuticals is an emerging player developing alpha-emitting radiotherapies (notably for hematologic malignancies) and shares Convergent's emphasis on Ac-225–based targeted therapy, though its current focus is on different oncology indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ConvergentRx
• LinkedInlinkedin.com/company/convergent-therapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Convergent Therapeutics